
|Articles|November 8, 2004
OIG study on Medicaid drug prices infuriates R.Ph.s
A recent Office of Inspector General study of how much states pay R.Ph.s for Medicaid drugs outrages some industry leaders. "I'm disgusted," said John Coster, VP of the National Association of Chain Drug Stores. "Instead of a real analysis of the program, they restate the obvious, which is that states pay [for Medicaid drugs] differently. With all due respect, it reflects a trend of OIG reports that lack methodological rigor."
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Explaining COVID-19 Vaccine Side Effects to Anxious Patients
3
Expert Discusses Flu and COVID-19 Vaccine Guidance
4
Hormone Replacement Therapy May Lower Dementia Risk in Postmenopausal Women
5







































